Latest Breaking News On - Virology therapeutic area head - Page 1 : comparemela.com

Gilead Sciences, Inc : Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024

Key Findings from PBC, HDV, HCV, HBV and MASH/Fibrosis Studies Affirm Commitment to Drive Life-changing Science in Liver Disease - Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research

Foster cityUnited statesFrank duffJacquie rossEpatitec mettiamociMeaghan smithGilead on twitter sciencesGilead sciences in liver diseaseGilead sciencesLove your liver campaignDrug administrationEuropean commissionGilead public affairsExchange commissionGilead sciences incWorld health organization

Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024

Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesFoster cityFrank duffEpatitec mettiamociGilead sciences in liver diseaseEuropean commissionGilead sciences incLove your liver campaignExchange commissionGilead sciencesDrug administrationWorld health organizationEuropean associationSenior vice presidentVirology therapeutic area headHepatitisc let

FDA Expands Indication for Gilead s (GILD) Vemlidy to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

FDA Expands Indication for Gilead s (GILD) Vemlidy to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Chaun hao linFrank duffGilead pediatric centerGilead sciencesGilead sciences incRisk of developmentDrug administrationAmerican associationLiver diseasesEuropean associationAssociate professorClinical pediatrics krek schoolSenior vice presidentVirology therapeutic area headWorsening renal impairmentSevere hepatomegaly

FDA Expands Indication for Gilead s Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

FDA Expands Indication for Gilead s Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFoster cityJacquie rossChaun hao linMeaghan smithFrank duffGilead sciences incGilead public affairsRisk of developmentExchange commissionDrug administrationGilead pediatric centerGilead sciences in liver diseaseGilead sciencesSafety profileOnce daily vemlidy demonstrated

FDA Approves Expanded Indication for Tenofovir Alafenamide as Hepatitis B Treatment

The new indication includes pediatric patients aged 6 years and older who weigh at least 25 kg and have compensated liver disease.

United statesTenofovir alafenamideChaun hao linFrank duffGilead sciences incGilead sciencesVirology therapeutic area head at gilead sciencesUniversity of southern californiaKrek school of medicineAmerican associationLiver diseaseEuropean associationZhao linKrek schoolSouthern californiaVirology therapeutic area head